Light Study Termination 'Positive' for Orexigen (OREX), Leerink Partners Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Buy This Dip in Orexigen (OREX), RBC Capital Says
May 13, 2015 6:35 AM EDTRBC Capital analyst Simos Simeonidis said with everyone pilling on against Orexigen Therapeutics (NASDAQ: OREX) they are buyers on this dip. The firm reiterated an Outperform rating and price target of $14.00.
Simeonidis said they spoke with CEO, Mike Narachi, who told them he "adamantly refutes the assertions that the company misled investors and patients." He was defiant in regards to today's news and defended Orexigen's handling of the LIGHT trial data. He told us that there was a data access plan in place, it was followed, and it actually had provisions for... More
UPDATE: Orexigen Therapeutics (OREX) and Takeda in Arbitration Over Terms of Deal
May 12, 2015 4:25 PM EDT(Updated - May 12, 2015 4:27 PM EDT)
Orexigen Therapeutics (NASDAQ: OREX) and Takeda are in arbitration on terms of collaboration, the company's CEO says in Bank of America presentation, according to CNBC's Meg Tirrell.
... More
Orexigen Therapeutics (OREX) Defended at Leerink
May 12, 2015 1:52 PM EDTOrexigen Therapeutics (NASDAQ: OREX) was defended a Leerink amid controversy after the company's Light trial was halted. Comments follow criticism in Forbes, which may have triggered a sell-off in the stock. In the view of analyst Paul Matteis, Light data showed what was expected -- safety and a positive trend.
"After OREX and Takeda announced the termination of the LIGHT study this morning, a Forbes article just disclosed data from the 50% interim analysis of the LIGHT study. Consistent with our... More
Orexigen Therapeutics (OREX) Mentioned Cautiously at Forbes
May 12, 2015 11:20 AM EDTOrexigen Therapeutics (NASDAQ: OREX) was mentioned cautiously in a Forbes article discussing results of its Light study of Contrave (link here).
... MoreTakeda, Orexigen Therapeutics (OREX) Announce Early Termination of Light Study
May 12, 2015 8:34 AM EDTTakeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a... More
